Market Overview

Wedbush Securities Reiterates Outperform Rating, $70 PT on Sarepta Therapeutics

Share:
Related
Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval
Mid-Day Market Update: Starwood Hotels Jumps Following CEO Resignation; CoStar Group Shares Slide
Sarepta Therapeutics' (SRPT) CEO Chris Garabedian on Q4 2014 Results -- Earnings Call Transcript (Seeking Alpha)

In a report published Monday, Wedbush Securities reiterated its Outperform rating and $70 price target on Sarepta Therapeutics (NASDAQ: SRPT).

Wedbush noted, “We reiterate our OUTPERFORM rating and 12-month price target of $70 per share. We arrive at our $70 per share 12-month price target by taking an average of two price targets, based upon a) early approval based on this data or b) or the requirement for another study. Scenario a. yields a $78 price target derived from a 3x multiple on our estimate of peak eteplirsen sales ($450M) plus peak sales of the two follow on compounds ($450M) discounted 50% for their early stage. Scenario b. yields a $62 price discounting our $78 price target back 1 year, to account for the potential need for an additional study.”

Sarepta Therapeutics closed on Friday at $29.34.

Latest Ratings for SRPT

DateFirmActionFromTo
Feb 2015Cowen & CompanyDowngradesOutperformMarket Perform
Feb 2015Bank of AmericaUpgradesBuy
Jan 2015WedbushInitiates Coverage onNeutral

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Reiteration Analyst Ratings

 

Related Articles (SRPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content